Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Giant Cell Arteritis: Real-life Experience

Peter M. Villiger
The Journal of Rheumatology September 2021, 48 (9) 1354; DOI: https://doi.org/10.3899/jrheum.210334
Peter M. Villiger
1P.M. Villiger, MD, Full Professor of Rheumatology and Clinical Immunology em, University of Bern, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter M. Villiger
  • For correspondence: Peter.villiger@hin.ch
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Giant cell arteritis (GCA), the most frequent form of vasculitis in the elderly, still poses questions regarding optimal treatment. Because of the risk of permanent vision loss, the revised European League Against Rheumatism recommendation of 2018 stresses that glucocorticoid (GC) therapy should start as soon as a diagnosis of GCA is strongly suspected.1 This initiates a GC exposure with a high risk of side effects such as fractures and infections.

Two randomized controlled trials (RCTs) have shown that blockade of the interleukin (IL)-6 pathway using tocilizumab (TCZ), a monoclonal antibody binding the IL-6 receptor chain, leads to a significant reduction of cumulative GC and a reduced relapse rate.2,3 In addition, 30–50% of patients stayed in remission over more than 2 years after discontinuation of a 12-month treatment with TCZ. These data strongly suggest a very profound effect of TCZ on pathogenic events.

In this issue of The Journal of Rheumatology, the retrospective observational multicenter study by Clément, et al meticulously analyzes the performance of TCZ in the real-world setting.4 The primary focus is on relapse rate, but the authors also report on safety and long-term outcome. Relapse is defined as therapeutic escalation. In brief, time from diagnosis to first TCZ administration (i.e., inclusion in the study) was 511 days, the relapse rate before inclusion was 72% (1.26/patient-yr), and the cumulative steroid prescription was 9.4 g/year. After inclusion, patients were followed over 842 days; cumulative GC prescription dropped to 2.1 g/year. Twenty-six of the 43 discontinued TCZ after a median of 279 days. Sixty percent of patients received a concomitant treatment with methotrexate.

The study adds important real-world data that support the findings of the RCTs regarding a steroid-sparing effect and reduction of relapses. Importantly, the remission rate after termination of treatment was lower than reported in the long-term data of the RCTs—possibly due to long-standing disease activity in the majority of patients.

Noteworthy is the fact that C-reactive protein levels rose under TCZ treatment in 60% of relapses. The authors report that TCZ doses were gradually reduced in cases of stable remission. This reduction may explain the findings and nicely shows a dose effect of TCZ on the suppression of the acute-phase response.

Four variables for predicting relapse were detected (i.e., start of TCZ later than 6 months after diagnosis, need of GC ≥ 5 mg prednisone, high relapse rate [> 0.8/yr], no ischemic signs at diagnosis). The fourth variable is a surprise as this is counterintuitive and not supported by earlier data about vision loss. As it stands, the identified variables may argue for an earlier introduction of TCZ. A finding of concern is the high mortality rate. Three elderly patients under TCZ treatment died because of infection.

This may be mere chance, but it suggests that age and concomitant GC treatment pose an important increase in mortality risk, which is higher as compared to data in patients with rheumatoid arthritis.

In summary, the study of Clément, et al confirms a clinically important GC-sparing effect of TCZ and a significantly reduced relapse rate under IL-6 inhibition therapy.4 As compared to the long-term data of the 2 RCTs,2,3 relapse rate after termination of TCZ treatment was higher. Further, the high number of lethal infections has to raise awareness. Taken together, this study4 supports early use of TCZ and may suggest a more systematic and rapid reduction of GCs in order to reduce side effects.

Footnotes

  • PMV receives speaker, advisory fees, and research support from Roche, MSD, AbbVie, Pfizer, Novartis, Grünenthal, Amgen, Sanofi, Chugai, BMS, and Gilead.

  • See Tocilizumab in GCA, page 1435

REFERENCES

  1. 1.↵
    1. Villiger PM,
    2. Adler S,
    3. Kuchen S,
    4. Wermelinger F,
    5. Dan D,
    6. Fiegeet V, et al.
    Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921-7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Stone JH,
    2. Tuckwell K,
    3. Dimonaco S,
    4. Klearman M,
    5. Aringer M,
    6. Blockmans D, et al.
    Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317-28.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Hellmich B,
    2. Agueda A,
    3. Monti S,
    4. Buttgereit F,
    5. de Boysson H,
    6. Brouwer E, et al.
    2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79:19-30.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Clément J,
    2. Duffau P,
    3. Constans J,
    4. Schaeverbeke T,
    5. Viallard JF,
    6. Barcat D, et al.
    Real-world risk of relapse of giant cell arteritis treated with tocilizumab: a retrospective analysis of 43 patients. J Rheumatol 2021;48:1435-41.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 9
1 Sep 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Giant Cell Arteritis: Real-life Experience
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Giant Cell Arteritis: Real-life Experience
Peter M. Villiger
The Journal of Rheumatology Sep 2021, 48 (9) 1354; DOI: 10.3899/jrheum.210334

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Giant Cell Arteritis: Real-life Experience
Peter M. Villiger
The Journal of Rheumatology Sep 2021, 48 (9) 1354; DOI: 10.3899/jrheum.210334
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Reversing the Tide of the Growing Burden of Avoidable Musculoskeletal Pain and Disability
  • Interferon Response Gene Score in Juvenile Dermatomyositis
  • Revisiting Magnetic Resonance Imaging Structural Lesions in the Sacroiliac Joints
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire